A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes [0.03%]
HS与NICE技术评估报告比较分析：评估泪眼患者治疗严重角膜炎的Ikervis药效研究报告
Yasmina Iffet Eroglu
Yasmina Iffet Eroglu
Background: In 2015, Ikervis® became the only EMA-approved cyclosporine A (CsA) eye-drop for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. Since th...
Quantifying the persisting orphan-drug shortage public health crisis in the United States [0.03%]
量化美国持续存在的孤儿药短缺公共卫生危机
Szymon Jarosławski,Chiraz Azaiez,Daria Korchagina et al.
Szymon Jarosławski et al.
Background: Orphan drugs (ODs) are pharmaceuticals manufactured for rare conditions that affect less than 200,000 people in the US. ODs are therefore produced in small quantities to meet sparse demand. Since 2010, OD shortages have become f...
Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines [0.03%]
迈向更加透明的波兰卫生技术评估流程：新的波兰卫生技术评估方法指南
Krzysztof Lach,Michal Dziwisz,Cécile Rémuzat et al.
Krzysztof Lach et al.
Introduction: Health technology assessment (HTA) in Poland supports reimbursement decisions via the Polish HTA Agency (AOTMiT), whose guidelines were updated in 2016. Methods: We identified key changes introduced by the update and, before g...
Dávid Dankó,Márk Péter Molnár
Dávid Dankó
In 2014, balanced assessment systems (BAS) were proposed as a resource-conscious, 'fit-for-purpose' form of health technology assessment for middle-income countries which lack resources and competences necessary for resource-intensive healt...
Policy implementation for methicillin-resistant Staphylococcus aureus in seven European countries: a comparative analysis from 1999 to 2015 [0.03%]
欧洲七国1999年至2015年的耐甲氧西林金黄色葡萄球菌政策实施情况：比较分析
Takuya Kinoshita,Hironobu Tokumasu,Shiro Tanaka et al.
Takuya Kinoshita et al.
Background: Policies to reduce methicillin-resistant Staphylococcus aureus (MRSA) infections, both healthcare-acquired (HA-MRSA) and livestock-associated (LA-MRSA) are implemented Europe-wide, but evaluations are difficult for countries yet...
Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment [0.03%]
法国药品卫生经济学评价报告分析——透视CEESP评价体系的内在理念
Mondher Toumi,Anastasiia Motrunich,Aurélie Millier et al.
Mondher Toumi et al.
Background: Despite the guidelines for Economic and Public Health Assessment Committee (CEESP) submission having been available for nearly six years, the dossiers submitted continue to deviate from them, potentially impacting product prices...
Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region [0.03%]
欧洲地区类风湿关节炎生物制剂的患者可及性分析
Zoltán Kaló,Zoltán Vokó,Andrew Östör et al.
Zoltán Kaló et al.
Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their ...
Drug pricing and reimbursement information management: processes and decision making in the global economy [0.03%]
药物定价和保险信息管理：全球环境下的流程与决策制定
Dimitrios Tsourougiannis
Dimitrios Tsourougiannis
Background: Cost-containment initiatives are re-shaping the pharmaceutical business environment and affecting market access as well as pricing and reimbursement decisions. Effective price management procedures are too complex to accomplish ...
Direct cost analysis of the second year post-allogeneic hematopoietic stem cell transplantation in the Bone Marrow Transplant Centre of Tunisia [0.03%]
突尼斯骨髓移植中心异基因造血干细胞移植术后第二年的直接费用分析
Myriam Razgallah Khrouf,Leila Achour,Asma Thabti et al.
Myriam Razgallah Khrouf et al.
Background: Hematopoietic stem cell transplantation (HSCT) is a medically complicated therapy with a long recovery time. In Tunisia, the National Health Insurance Fund (CNAM) covers only the first year post-transplantation, after which the ...
Use and cost comparison of clobazam to other antiepileptic drugs for treatment of Lennox-Gastaut syndrome [0.03%]
克洛巴唑用于治疗兰诺克斯-加斯特综合征的使用情况及与其它抗癫痫药物的成本比较研究
Clément François,John M Stern,Augustina Ogbonnaya et al.
Clément François et al.
Background: Lennox-Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy associated with serious injuries due to frequent and severe seizures. Of the antiepileptic drugs (AEDs) approved for LGS, clobazam is a more recent marke...